As a CEO, issues and decisions come to the table multiple times every day. You need to decide on which issues to intervene, ...

D. Boral Capital keeps a Buy rating on Anavex Life Sciences (AVXL) with a $46 price target after Cassava Sciences’ (SAVA) Phase 3 trial for simufilam in mild-to-moderate Alzheimer’s disease ...

Craft Capital Management LLC acted as the representative of the underwriters, with D. Boral Capital LLC acting as the co-underwriter, for the Offering. The common shares of the Offering referenced ...

NEW YORK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- D. Boral Capital, a relationship-performance driven investment bank focused on high quality mid-market & growth issuers and investors, today provided a ...

Enjoy exclusive member discounts, giveaways and competitions with our subscriber rewards program. Enter HereElevate your Scorchers experience with tickets to Legends Lounge! You’ll enjoy great seating ...